

Long-term quality of life in adult craniopharyngioma patients: correlation with pituitary stalk section after endoscopic endonasal surgery

*Original*

Long-term quality of life in adult craniopharyngioma patients: correlation with pituitary stalk section after endoscopic endonasal surgery / Portonero, I., Bue, E.L., Pesaresi, A., Antico, A., Sgambetterra, S., De Marco, R., Penner, F., Garbossa, D., Lanotte, M.M.R., Zenga, F.. - In: ACTA NEUROCHIRURGICA. - ISSN 0942-0940. - (2026).  
[10.1007/s00701-026-06902-7]

*Availability:*

This version is available at: 11583/3013088 since: 2026-07-14T07:13:07Z

*Publisher:*

Springer

*Published*

DOI:10.1007/s00701-026-06902-7

*Terms of use:*

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

*Publisher copyright*

(Article begins on next page)

# Long-term quality of life in adult craniopharyngioma patients: correlation with pituitary stalk section after endoscopic endonasal surgery

Received: 03 Feb 2026

Accepted: 01 May 2026

Published online: 22 May 2026

Irene Portonero, Enrico Bue, Alessandro Pesaresi, Alice Antico, Silvia Sgambetterra, Raffaele Marco, Federica Penner, Diego Garbossa, Michele Lanotte & Francesco Zenga

Cite this article as: Portonero, I., Bue, E., Pesaresi, A. *et al.* Long-term quality of life in adult craniopharyngioma patients: correlation with pituitary stalk section after endoscopic endonasal surgery. *Acta Neurochir* (2026). <https://doi.org/10.1007/s00701-026-06902-7>

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

If this paper is publishing under a Transparent Peer Review model then Peer Review reports will publish with the final article.

## Long-term quality of life in adult craniopharyngioma patients: correlation with pituitary stalk section after endoscopic endonasal surgery

Irene Portonero MD<sup>1,2</sup>, Enrico Lo Bue MD<sup>1,2</sup>, Alessandro Pesaresi MD<sup>1,2</sup>, Alice Antico MD<sup>1,2</sup>, Silvia Sgambetterra MD<sup>1,2</sup>, Raffaele De Marco MD<sup>1,2</sup>, Federica Penner MD<sup>1,2</sup>, Diego Garbossa MD, PhD<sup>2</sup>, Michele M.R. Lanotte MD<sup>2</sup>, Francesco Zenga MD<sup>1,2</sup>

<sup>1</sup> Pituitary and Skull Base Surgery Unit, “Città della Salute e della Scienza” University Hospital, Turin, Italy.

<sup>2</sup> Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.

### Corresponding Author:

Enrico Lo Bue

“Città della Salute e della Scienza” University Hospital, Turin, Corso Bramante 88, 10126 Turin, Italy  
enrico.lobue@unito.it

**Keywords:** quality of life; craniopharyngioma; endoscopic endonasal approach; pituitary stalk

### Statements and Declarations

**Funding:** No funding was received for conducting this study.

**Competing Interests:** The authors have no competing interests to declare that are relevant to the content of this article.

**Ethics approval:** All clinical and radiological data were collected and retrospectively analyzed. This study does not require any variations in patient’s treatment and no formal ethics committee approval was required. All procedures performed for this study were in accordance with the ethical standard of author’s Institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Abstract word count: 287

Text word count: 3494

Number of references: 43

Number of tables and/or figures: 8

Number of videos: 0

### Abbreviations:

Quality of life (QoL), Cerebrospinal fluid (CSF), Extent of resection (EOR), Gross total resection (GTR), Endoscopic endonasal approach (EEA), CT angiography (CTA), Hormone replacement therapy (HRT), Postoperative day (POD), World Health Organization (WHO), Lumbar drain (LD), External ventricular drain (EVD), Subtotal resection (STR), Growth hormone (GH) Karnofsky Performance Scale (KPS), Health-related QoL (HRQoL)

## **Abstract**

**Purpose:** Craniopharyngiomas are benign but locally aggressive tumors whose surgical treatment poses a challenge due to their proximity to critical structures. While gross total resection (GTR) may reduce recurrence risk, it often leads to significant long-term morbidity, especially when the pituitary stalk is sacrificed. This study aims to assess health-related quality of life (QoL) in adult patients undergoing endoscopic endonasal approach (EEA) for craniopharyngioma, with a focus on the impact of pituitary stalk section.

**Methods:** We retrospectively analyzed 35 adult patients who underwent EEA for histologically confirmed craniopharyngioma between April 2012 and September 2023. Inclusion criteria were age >18 years and at least one year of follow-up. Patients completed a custom 8-item telephone questionnaire assessing the impact of hormone replacement therapy (HRT), visual changes, hypothalamic dysfunction (sleep, appetite, sexual and behavioral disturbances), and nasal or olfactory symptoms. Each item was rated on a 1–5 scale, and patients identified the most burdensome symptom.

**Results:** Older patients (>55 years), those without preoperative panhypopituitarism, and those with postoperative hormonal decline reported higher impact. Visual deficits significantly affected QoL, particularly when vision worsened postoperatively. Obese patients (BMI >30) reported greater impact from weight gain. Sleep disturbances were more prevalent in adamantinomatous craniopharyngiomas, while behavioral changes were more frequent in older patients. Smokers reported more nasal breathing issues. Sexual dysfunction was more frequently reported by males, older patients, and those who had stalk resection or new endocrine deficits. Stalk section was significantly associated with higher GTR rates but also with worsened endocrine function and higher cumulative QoL burden.

**Conclusions:** Pituitary stalk resection increases GTR likelihood but at the cost of greater long-term endocrine morbidity. Patient age and baseline function significantly influence postoperative QoL, underscoring the importance of individualized surgical planning.

## **Introduction**

Craniopharyngiomas are complex tumors with a significant impact on patients' quality of life (QoL), both from surgical and endocrinological perspectives. Their location near critical structures such as the optic chiasm and pituitary stalk makes surgical management particularly challenging due to the risk of postoperative complications [17, 31, 24].

Effective treatment requires a multidisciplinary approach both before and after surgery. Endocrinologists assess hypothalamic-pituitary function and manage hormone replacement therapy as needed. Ophthalmologists evaluate visual field deficits often caused by optic pathway compression. When possible, collaboration with ENT surgeons is recommended to assist with harvesting the nasoseptal flap and managing postoperative care, including the treatment of cerebrospinal fluid (CSF) leaks. Neurosurgeons are responsible for selecting the surgical approach that best balances the extent of resection (EOR) with the risk of complications. Despite comprehensive evaluation and treatment planning, craniopharyngioma patients often experience significantly reduced QoL due to the effects of tumor growth and surgical intervention [18, 7, 11, 30]. After over a decade of experience managing these tumors, our team sought to evaluate the long-term impact of surgery on patients' QoL.

In particular, the sectioning of the pituitary stalk has been associated with higher rates of gross total resection (GTR) but may also contribute to worsened long-term outcomes [17, 28, 39]. One of the main goals of this study was to assess how pituitary stalk sacrifice affects patients' QoL over time. To this end, we retrospectively analyzed a cohort of 35 patients who underwent endoscopic endonasal approach (EEA) for craniopharyngioma, with a specific focus on QoL outcomes and the factors most closely associated with postoperative impairment.

## **Methods**

This study is a retrospective single-center analysis of patients with craniopharyngioma who underwent endoscopic endonasal surgery between April 2012 and September 2023 at the authors' institution. Inclusion criteria were age over 18 years, histologically confirmed craniopharyngioma, treatment via EEA, and at least one year of follow-up. Exclusion criteria included alternative histological diagnoses and transcranial or transventricular surgical approaches. All patients received preoperative endocrinological evaluation to assess hypothalamic-pituitary function and determine the need for hormone replacement therapy (HRT). Visual function was assessed preoperatively via computerized visual field testing. In urgent cases, endocrinological evaluation was performed postoperatively, and ophthalmologic assessment was deferred to three months after surgery.

Preoperative ENT evaluation was conducted to assess nasal anatomy. All patients underwent contrast-enhanced MRI with pituitary protocol to define tumor morphology and relationships with adjacent structures. CT angiography (CTA) was performed to evaluate vascular anatomy, including the relationship of the lesion with internal carotid and anterior cerebral arteries. MRI and CTA datasets were fused for intraoperative neuronavigation.

Postoperatively, copeptin levels and fluid balance were monitored every 12 hours. Daily evaluations included serum electrolytes, blood glucose, plasma and urine osmolality to allow early diagnosis of central diabetes insipidus and guide Desmopressin therapy. On postoperative day 2 (POD-2), cortisol levels were

measured to assess adrenal function. In patients already receiving corticosteroids, cortisol was not measured and Cortisone Acetate was continued prophylactically. ENT follow-up was performed on POD-2 and POD-7 to assess the mucosal flap and detect bleeding or CSF leaks. Subsequent ENT evaluations were scheduled based on symptoms. Multidisciplinary follow-up (endocrinological and neurosurgical) was conducted one month after surgery, followed by neurosurgical assessments at six months and annually. Endocrine follow-up was tailored individually. Patients with preoperative visual deficits underwent ophthalmologic re-evaluation three months after surgery or earlier in case of visual worsening.

#### Quality of life assessment

In all patients with at least one year of follow-up, QoL was assessed using a questionnaire specifically developed by the authors, as no validated instruments currently available in the literature comprehensively address the multiple QoL domains relevant to adult patients with craniopharyngiomas treated via an endoscopic endonasal approach.

The survey was administered by telephone and explored the following postoperative domains: need for HRT, visual disturbances, hypothalamic dysfunction (including alterations in appetite, sleep, sexual function, and personality), nasal breathing difficulties, ageusia and/or anosmia. For each domain, the impact on QoL was rated on a 5-point numerical scale, and patients were also asked to indicate the factor with the greatest overall impact. The questionnaire items are shown in Fig. 1.

**Endocrinological Disorders**

1. After surgery, did you need to start taking medications to compensate for an endocrinological deficit that you did not have before the operation?  
If yes, on a scale from 1 to 5, how much did this affect your quality of life?

**Visual Deficits**

2. After surgery, did you experience a worsening of vision compared to before the operation?  
If yes, on a scale from 1 to 5, how much did this affect your quality of life?

**Hypothalamic Disorders**

3. After surgery, did you experience increased appetite and possible weight gain compared to before the operation?  
If yes, on a scale from 1 to 5, how much did this affect your quality of life?
4. After surgery, did you experience increased sleepiness or new sleep disturbances that were not present before the operation?  
If yes, on a scale from 1 to 5, how much did this affect your quality of life?
5. After surgery, did you experience sexual dysfunction not related to LH/FSH deficiency and not present before the operation?  
If yes, on a scale from 1 to 5, how much did this affect your quality of life?
6. After surgery, did you experience behavioral disturbances or personality changes compared to before the operation?  
If yes, on a scale from 1 to 5, how much did this affect your quality of life?

**Nasal Disorders**

7. After surgery, did you experience empty nose sensation, difficulty breathing through the nose, anosmia and/or ageusia that were not present before the operation?  
If yes, on a scale from 1 to 5, how much did this affect your quality of life?

**Final Question**

Which aspect of your life was most affected after surgery?

**Fig. 1** Questionnaire developed by the authors and administered by telephone to the patient cohort

**Statistical analysis**

Descriptive statistics were reported as the mean and standard deviation for continuous variables and as frequency and percentage for nominal variables. The Shapiro-Wilk test was performed to assess the normality of the data distribution. Levene's test was used to evaluate the equality of variances. Differences between two groups were assessed using the Mann-Whitney U test or the Student's t-test for independent samples, depending on the assumptions met. Associations between nominal variables were evaluated using the chi-square ( $\chi^2$ ) test as a univariate analysis. Subsequently, a multivariate analysis model was constructed using binary logistic regression, considering the variables that were statistically significant in the univariate analysis. A p-value less than <0.05 was considered statistically significant. Statistical analyses were performed using SPSS software (version 25.0) and Jamovi software (Jamovi project [2019]. Jamovi [version 2.3.26.0] [computer software]; <https://www.jamovi.org>).

## Results

A total of 35 patients were included (14 females, 40%; 21 males, 60%), with a mean age of 54.5 years (range 28–75). Five patients were excluded because they were treated using a transventricular (3/5) or transcranial approach (2/5). Based on this, patients were divided into two groups: Group 1 (<55 years, n=17; 48.6%) and Group 2 (>55 years, n=18; 51.4%). Preoperatively, 20 patients (57.1%) had a BMI <30, and 15 (42.9%) had a BMI >30. At the time of surgery, 22 (62.9%) were non-smokers, while 13 (37.1%) were smokers. From an endocrinological standpoint, 11 patients (31.4%) presented with panhypopituitarism, and 24 (68.6%) had either isolated hormonal deficits or preserved pituitary function. Diabetes insipidus was present in 8 patients (22.9%). Visual deficits were observed in 24 patients (68.6%). Histologically, 19 cases (54.3%) were adamantinomatous and 16 (45.7%) papillary craniopharyngiomas, according to World Health Organization (WHO) 2021 classification.

Postoperative complications occurred in 14 patients (40%). Specifically, 7 had CSF leaks, 5 experienced hemorrhage, 4 developed pneumocephalus, and 5 had infections (2 meningitis, 2 pneumonia, 1 abdominal wound infection). Endocrine function improved or remained stable in 17 patients (48.6%), while 18 (51.4%) showed postoperative worsening. Visual function improved in 15 patients (42.9%), whereas 20 patients (57.1%) had stable or worsened deficits. Only one patient experienced a mild subjective worsening of overall visual acuity; therefore, stable and worsened cases were grouped into a single category.

During follow-up, recurrence or residual tumor growth occurred in 9 patients (25.7%). Among them, 8 (22.9%) received adjuvant radiotherapy, and 1 (2.9%) underwent reoperation. The mean follow-up duration was 82 months (median: 91.5 months; range: 12–156 months).

Detailed clinical and demographic data are summarized in Table 1.

**Table 1** Descriptive results

|                                        | No. of patients    | %           |
|----------------------------------------|--------------------|-------------|
| <b>Sex</b>                             | F:M 14:21          | 40%:60%     |
| <b>Age (mean value)</b>                | 54.5 (range 28-75) |             |
| Group 1 (<55 years)                    | 17                 | 48.6%       |
| Group 2 (>55 years)                    | 18                 | 51.4%       |
| <b>Preoperative BMI</b>                |                    |             |
| BMI>30                                 | 15                 | 42.9%       |
| BMI<30                                 | 20                 | 57.1%       |
| <b>Smoke</b>                           | Y:N 13:22          | 37.1%:62.9% |
| <b>Preoperative endocrine function</b> |                    |             |
| Anterior panhypopituitarism            | 11                 | 31.4%       |
| Diabetes insipidus                     | 8                  | 22.9%       |
| <b>Preoperative visual deficit</b>     | 24                 | 68.6%       |
| <b>Histopathology</b>                  |                    |             |
| Adamantinomatous                       | 19                 | 54.3%       |
| Papillary                              | 16                 | 45.7%       |
| <b>Surgical technique</b>              |                    |             |
| EEA                                    | 35                 | 100%        |
| Preoperative LD                        | 27                 | 77.1%       |
| Preoperative EVD                       | 2                  | 5.7%        |
| Fat graft                              | 35                 | 100%        |
| Hadad-Bassagasteguy flap               | 35                 | 100%        |
| Pituitary stalk resected               | 20                 | 57.1%       |



|                                         |      |       |
|-----------------------------------------|------|-------|
| Pituitary stalk preserved               | 15   | 42.9% |
| GTR                                     | 26   | 74.3% |
| STR                                     | 9    | 25.7% |
| <b>Postoperative Complications</b>      | 14   | 40%   |
| CSF leak                                | 7/14 | 50%   |
| Hemorrhage                              | 5/14 | 35.7% |
| Pneumocephalus                          | 4/14 | 28.6% |
| Infection                               | 5/14 | 35.7% |
| <b>Postoperative endocrine function</b> |      |       |
| Improvement/Stability                   | 17   | 48.6% |
| Worsening                               | 18   | 51.4% |
| <b>Postoperative visual function</b>    |      |       |
| Improvement                             | 15   | 42.9% |
| Worsening/Stability                     | 20   | 57.1% |
| <b>Recurrence/Residual growth</b>       | 9    | 25.7% |
| <b>Adjuvant radiotherapy</b>            | 8    | 22.9% |
| <b>Surgical reintervention</b>          | 1    | 2.9%  |

### Surgical evaluation

All patients underwent surgery via an extended EEA. A preoperative lumbar drain (LD) was placed in 27 of 35 patients (77.1%) and typically removed on POD-2, barring complications. In 2 patients (5.7%), an external ventricular drain (EVD) was urgently placed due to acute hydrocephalus. In all cases, a paraumbilical autologous fat graft and a pedicled nasoseptal flap were used for multilayer skull base reconstruction. The pituitary stalk was sectioned in 20 patients (57.1%) and preserved in 15 (42.9%). GTR was achieved in 26 cases (74.3%), while 9 patients (25.7%) underwent subtotal resection (STR).

Surgical details are summarized in Table 1.

### Quality of life assessment

The responses to the QoL questionnaire are summarized in Table 2. In the “Worst” column, patients indicated the factor with the greatest impact on their QoL. The most frequently reported were weight gain (9/35, 25.7%) and sexual dysfunction (7/35, 20%), followed by the need for HRT and visual deficits (6/35 each, 17.1%). Nasal breathing difficulties were identified by 5 patients (14.3%), while sleep and behavioral disturbances were each reported by 1 patient (2.9%).

**Table 2** Quality of life questionnaire results

| Patient | HRT | Vision | Weight | Sleep | Sexuality | Behavior | Nose | Worst     | Total |
|---------|-----|--------|--------|-------|-----------|----------|------|-----------|-------|
| 1       | 3   | 4      | 0      | 2     | 5         | 3        | 2    | Sexuality | 22    |
| 2       | 2   | 0      | 5      | 4     | 4         | 4        | 4    | Weight    | 25    |
| 3       | 4   | 1      | 4      | 1     | 1         | 4        | 5    | Nose      | 25    |
| 4       | 1   | 0      | 2      | 0     | 5         | 5        | 5    | Nose      | 18    |
| 5       | 1   | 2      | 1      | 1     | 0         | 2        | 0    | Vision    | 8     |
| 6       | 5   | 3      | 1      | 1     | 1         | 3        | 5    | Nose      | 21    |
| 7       | 1   | 5      | 2      | 3     | 4         | 1        | 5    | Nose      | 26    |
| 8       | 2   | 0      | 1      | 0     | 2         | 0        | 0    | HRT       | 5     |
| 9       | 1   | 2      | 5      | 4     | 5         | 0        | 0    | Weight    | 18    |
| 10      | 4   | 1      | 4      | 0     | 2         | 3        | 0    | HRT       | 18    |
| 11      | 3   | 2      | 2      | 4     | 0         | 0        | 4    | Sleep     | 20    |
| 12      | 2   | 0      | 5      | 2     | 4         | 1        | 0    | Weight    | 14    |

|    |   |   |   |   |   |   |   |           |    |
|----|---|---|---|---|---|---|---|-----------|----|
| 13 | 5 | 0 | 5 | 1 | 0 | 5 | 1 | Weight    | 22 |
| 14 | 3 | 0 | 0 | 2 | 4 | 0 | 0 | HRT       | 9  |
| 15 | 2 | 2 | 3 | 5 | 5 | 0 | 1 | Sexuality | 23 |
| 16 | 5 | 2 | 4 | 4 | 4 | 1 | 0 | HRT       | 21 |
| 17 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | Behavior  | 40 |
| 18 | 1 | 2 | 1 | 4 | 4 | 0 | 2 | Sexuality | 19 |
| 19 | 5 | 1 | 5 | 4 | 0 | 0 | 5 | Weight    | 24 |
| 20 | 5 | 5 | 0 | 0 | 0 | 0 | 4 | Vision    | 19 |
| 21 | 5 | 0 | 4 | 3 | 5 | 1 | 4 | HRT       | 30 |
| 22 | 4 | 5 | 4 | 4 | 4 | 4 | 0 | Vision    | 29 |
| 23 | 0 | 4 | 0 | 3 | 0 | 0 | 0 | Vision    | 9  |
| 24 | 3 | 0 | 3 | 3 | 3 | 0 | 0 | Sexuality | 12 |
| 25 | 4 | 5 | 2 | 0 | 0 | 0 | 5 | Nose      | 16 |
| 26 | 5 | 5 | 5 | 4 | 5 | 4 | 0 | Sexuality | 35 |
| 27 | 5 | 4 | 5 | 4 | 5 | 3 | 4 | Weight    | 33 |
| 28 | 5 | 5 | 0 | 4 | 0 | 0 | 0 | Vision    | 18 |
| 29 | 0 | 0 | 4 | 4 | 5 | 0 | 0 | Weight    | 13 |
| 30 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | HRT       | 1  |
| 31 | 3 | 0 | 0 | 0 | 3 | 1 | 2 | Sexuality | 10 |
| 32 | 5 | 5 | 5 | 5 | 5 | 0 | 0 | Vision    | 25 |
| 33 | 4 | 1 | 5 | 0 | 5 | 0 | 5 | Weight    | 22 |
| 34 | 3 | 0 | 3 | 4 | 4 | 3 | 3 | Sexuality | 22 |
| 35 | 3 | 0 | 5 | 2 | 4 | 0 | 2 | Weight    | 16 |

### Statistical analysis

Our analysis revealed several statistically significant findings regarding QoL in patients undergoing EEA for craniopharyngioma. Patients over 55 years reported a greater impact on QoL related to HRT compared to younger patients, with mean scores of  $3.67 \pm 1.68$  vs.  $2.59 \pm 1.50$  ( $p = 0.041$ ). A higher perceived burden was also observed in patients without preoperative anterior panhypopituitarism compared to those with existing deficits ( $3.54 \pm 1.61$  vs.  $2.27 \pm 1.49$ ;  $p = 0.033$ ), as well as in those who experienced postoperative endocrine worsening ( $3.72 \pm 1.36$  vs.  $2.53 \pm 1.77$ ;  $p = 0.041$ ). Moreover, patients with preoperative visual deficits reported greater QoL impairment than those without ( $3.58 \pm 1.81$  vs.  $2.18 \pm 1.83$ ;  $p = 0.032$ ).

Patients with stable or worsened visual deficit after surgery reported higher QoL impact scores ( $2.85 \pm 1.98$ ) compared to those who experienced visual improvement ( $0.93 \pm 1.58$ ;  $p = 0.005$ ), with females reporting greater discomfort than males ( $3.07 \pm 1.90$  vs.  $1.33 \pm 1.85$ ;  $p = 0.012$ ).

Postoperative weight gain had a greater impact in patients with a preoperative BMI  $>30$  ( $3.73 \pm 1.49$  vs.  $2.20 \pm 2.07$ ;  $p = 0.039$ ).

Sleep disturbances were more frequent in patients with adamantinomatous craniopharyngiomas compared to the papillary subtype ( $3.11 \pm 1.52$  vs.  $1.75 \pm 1.81$ ;  $p = 0.026$ ).

Although sexual dysfunction did not reach statistical significance overall, it was more frequently reported by males ( $3.33 \pm 1.80$  vs.  $2.36 \pm 2.34$ ), older patients ( $3.28 \pm 1.99$  vs.  $2.59 \pm 2.12$ ), and individuals who underwent pituitary stalk resection ( $3.50 \pm 1.96$  vs.  $2.20 \pm 2.01$ ). Higher scores were also observed in patients with worsened postoperative endocrine function ( $3.17 \pm 2.18$ ) and those who underwent GTR ( $3.23 \pm 1.92$  vs.  $2.11 \pm 2.32$ ).

Behavioral changes were more commonly reported in older patients ( $2.17 \pm 1.72$  vs.  $0.82 \pm 1.70$ ;  $p = 0.010$ ), while nasal breathing difficulties

were more frequent among smokers ( $3.23 \pm 2.05$  vs.  $1.41 \pm 1.92$ ;  $p = 0.023$ ).

#### Pituitary stalk resection

Pituitary stalk resection was significantly associated with a higher rate of GTR (18 vs. 8;  $p = 0.014$  univariate,  $p = 0.045$  multivariate), but also with worse postoperative endocrine outcomes (14 vs. 6;  $p = 0.011$  univariate,  $p = 0.031$  multivariate).

The “hypothalamic-pituitary function” score integrates the burden of endocrine therapy, weight issues, sexual dysfunction, sleep disorders, and behavioral changes. This was significantly higher in patients over 55 ( $15.1 \pm 5.31$  vs.  $10.7 \pm 5.53$ ;  $p = 0.048$ ) and in those who underwent stalk resection ( $14.8 \pm 5.79$  vs.  $10.5 \pm 5.44$ ;  $p = 0.034$ ).

Full statistical results are detailed in Table 3 and 4.

**Table 3** Statistically significant results

| Outcome variable                       | Independent variable               | Comparison                         | No. of patients | Mean $\pm$ SD                      | p-value      |
|----------------------------------------|------------------------------------|------------------------------------|-----------------|------------------------------------|--------------|
| <b>HRT</b>                             | Age                                | <55 yrs vs >55 yrs                 | 17 vs 18        | $2.59 \pm 1.50$ vs $3.67 \pm 1.68$ | <b>0.041</b> |
|                                        | Preop. anterior panhypopituitarism | No vs Yes                          | 24 vs 11        | $3.54 \pm 1.61$ vs $2.27 \pm 1.49$ | <b>0.033</b> |
|                                        | Preop. visual deficit              | No vs Yes                          | 11 vs 24        | $2.18 \pm 1.83$ vs $3.58 \pm 1.81$ | <b>0.032</b> |
|                                        | Postop. endocrine function         | Improvement/Stability vs Worsening | 17 vs 18        | $2.53 \pm 1.77$ vs $3.72 \pm 1.36$ | <b>0.041</b> |
| <b>Visual deficit</b>                  | Sex                                | Female vs Male                     | 14 vs 21        | $3.07 \pm 1.90$ vs $1.33 \pm 1.85$ | <b>0.012</b> |
|                                        | Postop. visual function            | Improvement vs Worsening/Stability | 15 vs 20        | $0.93 \pm 1.58$ vs $2.85 \pm 1.98$ | <b>0.005</b> |
| <b>Weight gain</b>                     | BMI                                | <30 vs >30                         | 20 vs 15        | $2.20 \pm 2.07$ vs $3.73 \pm 1.49$ | <b>0.039</b> |
| <b>Sleep disorders</b>                 | Histopathology                     | Adamantinomatous vs Papillary      | 19 vs 16        | $3.11 \pm 1.52$ vs $1.75 \pm 1.81$ | <b>0.026</b> |
| <b>Behavioral disorders</b>            | Age                                | <55 yrs vs >55 yrs                 | 17 vs 18        | $0.82 \pm 1.70$ vs $2.17 \pm 1.72$ | <b>0.010</b> |
| <b>Nasal disorders</b>                 | Smoking                            | No vs Yes                          | 22 vs 13        | $1.41 \pm 1.92$ vs $3.23 \pm 2.05$ | <b>0.023</b> |
| <b>Hypothalamic–pituitary function</b> | Age                                | <55 yrs vs >55 yrs                 | 17 vs 18        | $10.7 \pm 5.5$ vs $15.1 \pm 5.3$   | <b>0.048</b> |
|                                        | Pituitary stalk                    | Preserved vs Resected              | 15 vs 20        | $10.5 \pm 5.4$ vs $14.8 \pm 5.8$   | <b>0.034</b> |

**Table 4** Statistically significant results of pituitary stalk management analysis

| Variable                                | Pituitary stalk |           |          | p-value (univ.) | p-value (multi.) |
|-----------------------------------------|-----------------|-----------|----------|-----------------|------------------|
|                                         | Total           | Preserved | Resected |                 |                  |
| <b>EOR</b>                              |                 |           |          | <b>0.014</b>    | <b>0.045</b>     |
| STR                                     | 9               | 7         | 2        |                 |                  |
| GTR                                     | 26              | 8         | 18       |                 |                  |
| <b>Postoperative endocrine function</b> |                 |           |          | <b>0.011</b>    | <b>0.031</b>     |
| Improvement/Stability                   | 17              | 11        | 6        |                 |                  |
| Worsening                               | 18              | 4         | 14       |                 |                  |

## **Discussion**

Craniopharyngiomas are WHO grade I tumors [19]. Despite their benign histopathology, their proximity to critical structures, such as pituitary gland, optic chiasm, hypothalamus, and third ventricle, often results in significant neurological and endocrinological complications, both from the tumor itself and from its treatment. As these patients typically require lifelong medical care and monitoring, identifying modifiable factors that impact postoperative QoL is of paramount importance [20].

While the impact of craniopharyngioma on QoL has been well documented in pediatric populations [4, 23], data on adult patients remain scarce. In 2021, Lucia et al. evaluated QoL in a cohort of 20 adults, highlighting that over half were unable to resume their preoperative job functions. However, 78% maintained social independence in daily life [20]. Notably, this study did not investigate preoperative factors that might predict postoperative QoL. Another recent study conducted by Mineni et al. proposed an additional scoring system for postoperative QoL assessment. However, unlike our study, it did not specifically focus on patients undergoing endoscopic endonasal surgery, nor did it evaluate the relationship between QoL outcomes and pituitary stalk sectioning. [44] To address this gap, we conducted a study assessing long-term QoL in adult craniopharyngioma patients, with a focus on identifying clinical and preoperative predictors of postoperative outcomes.


We administered a custom-designed questionnaire (Fig. 1) to 35 patients who had undergone surgery at least 12 months earlier, allowing for evaluation of long-term effects. The questionnaire addressed four main domains: (1) need for postoperative HRT; (2) visual deficits; (3) hypothalamic disturbances, including weight gain, sleep disorders, sexual dysfunction, and personality changes; and (4) nasal complications, including nasal breathing difficulty, ageusia, and anosmia. The following sections analyze the statistical correlations between questionnaire responses and clinical data to identify potential preoperative predictors of long-term QoL.

### **Hormone Replacement Therapy**

The need for postoperative HRT is a key factor affecting QoL in patients with craniopharyngioma. Central diabetes insipidus, a common postoperative complication, has been identified as a risk factor for depressive symptoms [18]. Although Desmopressin is generally effective in managing polyuria, its impact on overall QoL remains inconsistent, with many patients reporting ongoing challenges despite adequate symptom control [14, 27].

Our questionnaire specifically assessed the requirement for new endocrine therapies introduced after surgery and asked patients to rate their impact on QoL (scale 1–5). As shown in Table 2, patients requiring multiple hormone replacements reported significantly lower QoL. This is particularly relevant in adult and elderly populations, where adherence to complex medication regimens can be problematic [13]. Our findings suggest that patients with no or only partial endocrine deficits preoperatively experienced a greater decline in QoL post-surgery when faced with the burden of polypharmacy (Fig. 2). Additionally, patients with preoperative visual deficits tended to report lower QoL scores. These individuals often show limited postoperative improvement or

persistent visual impairment, and when combined with the demands of HRT, their overall burden increases, further diminishing QoL (Fig. 2).



**Fig. 2** Statistical analysis of HRT in relation to (A) age ( $p = 0.041$ ), (B) preoperative anterior panhypopituitarism ( $p = 0.033$ ), (C) postoperative worsening of endocrine function ( $p = 0.041$ ), and (D) presence of preoperative visual deficits ( $p = 0.032$ ). The circle indicates the mean, and the square indicates the median

#### Visual impairment

Visual impairment is a major determinant of reduced QoL in patients with craniopharyngioma, with an impact closely related to the severity of the deficit. Visual loss compromises autonomy, limits daily activities, and imposes a substantial psychological burden, often leading to frustration, reduced self-efficacy, and impaired social and occupational functioning [37].

Given that visual field deficits are among the main indications for surgical intervention, both in craniopharyngiomas and other sellar lesions such as pituitary adenomas, we evaluated postoperative visual outcomes in our cohort. Patients were asked whether they experienced new or worsened visual deficits following surgery and to rate the impact on their QoL (scale 1–5). As shown in Table 3, our findings are consistent with previous studies identifying visual impairment as a key predictor of poor QoL in this population, alongside hormonal dysfunction and elevated BMI [7].

Dekkers et al. demonstrated that visual field deficits are the strongest independent predictor of low QoL in adults with craniopharyngioma, correlating with depression, fatigue, and reduced motivation [11]. Similarly, Kawamata et al. reported that visual disturbances significantly lower functional performance postoperatively, as measured by the Karnofsky Performance Scale (KPS) and health-related QoL (HRQoL) indices [16] (Fig. 3).

Interestingly, in our cohort, visual impairment had a more pronounced negative effect on QoL in female patients. Although female sex is not a disease-specific predictor, it has been associated with lower QoL scores across multiple domains, including physical functioning, pain, fatigue, and social limitations [7, 11, 30]. While a direct link between visual impairment and sex-specific QoL differences has not been firmly established, our data suggest that women may experience greater psychosocial difficulty adapting to physical deficits (Fig. 3A).

### Obesity

Hypothalamic obesity significantly impairs long-term QoL in patients with craniopharyngioma, affecting both psychosocial well-being and metabolic health. Common long-term consequences include daytime sleepiness, fatigue, circadian rhythm disruption, gastrointestinal and pulmonary symptoms (e.g., diarrhea, dyspnea), memory deficits, and neuropsychological disturbances [41, 25]. In our questionnaire, patients were asked whether they had experienced increased appetite and/or weight gain after surgery, and to rate its impact on their QoL on a 5-point scale. Our findings suggest that patients with a high preoperative BMI may already suffer from the effects of hypothalamic obesity. For these individuals, additional weight gain can be particularly distressing, intensifying psychosocial issues such as anxiety, depression, disordered eating, and low self-esteem. Furthermore, weight gain compounds the physical complications of obesity, including diabetes, dyslipidemia, cardiovascular disease, ischemic stroke, and greater infection risk. Together, these factors significantly contribute to reduced QoL (Fig. 3B).

### Sleep disorders

Sleep disturbances are a major concern in patients with craniopharyngioma. These issues may arise from tumor-related damage to structures regulating the sleep–wake cycle, iatrogenic injury, or as a consequence of hypothalamic obesity. Hypothalamic dysfunction, particularly involving the suprachiasmatic nucleus, is central to the pathogenesis of sleep disorders [32].

In our cohort, patients with adamantinomatous craniopharyngioma reported more pronounced sleep disturbances than those with papillary tumors. This is difficult to interpret, as no current evidence supports a higher prevalence of hypothalamic dysfunction in either histological subtype (Fig. 3C).

However, up to 35% of patients with adamantinomatous craniopharyngioma exhibit signs of hypothalamic dysfunction, including sleep disruption, at diagnosis [21]. Postoperatively, hypothalamic dysfunction remains one of the main comorbidities in this group. Anatomically, adamantinomatous tumors often involve the sellar and suprasellar regions, frequently affecting the pituitary stalk, while papillary craniopharyngiomas typically arise in the third ventricle, often sparing the stalk [29].

This anatomical distinction may partly explain the higher rate of postoperative hypothalamic disturbances in adamantinomatous cases. Still, the significance of this finding could require further investigation.

### Sexual dysfunction

Sexuality is a complex domain influenced by neural, endocrinological, and genetic factors. Key neural structures involved include the limbic system - hypothalamus, amygdala, hippocampus, and septal nuclei - that regulate motivation and emotional processing. Notably, the medial preoptic area of the anterior hypothalamus integrates inputs to trigger sexual motivation [6]. Craniopharyngioma growth can damage the hypothalamus, pituitary gland, and stalk, causing gonadotropin deficiency and adult hypogonadism, which often results in sexual dysfunction and reduced libido [43, 33]. Additionally, GH deficiency has been linked to high rates of sexual dysfunction in both sexes [22]. Sexual well-being is a critical component of QoL, as sexual disorders may lower self-esteem and impair intimate relationships [7]. These changes affect not only the patient but also their social support network, underscoring the need to consider psychosocial factors in managing chronic illness [6].

### Behavioral disorders

Hypothalamic damage can impair functions such as feeding, sleep, reproduction, and thermoregulation. Due to its connections with the limbic system, emotional regulation is often affected. Psychiatric disorders frequently accompany changes in endocrine function, eating behavior, sleep, and autonomic regulation [1]. In the literature, many case reports describe craniopharyngiomas presenting with altered mental status, including rapidly progressive dementia, mania, catatonia, and psychosis [5, 36]. The high prevalence of socio-behavioral and emotional dysfunctions in these patients is likely multifactorial, involving frontal lobe dysfunction, hormonal imbalances, and hypothalamic/diencephalic impairment [42]. Additionally, oxytocin, which has been recognized as playing a fundamental role in social functioning, may be reduced in patients with hypopituitarism [9, 10].

Our findings show that behavioral and personality changes occur more frequently in older patients (Fig. 3D). This may be explained by the influence of physical and social factors together with the cumulative impact of past experiences and aging-specific stressors on mental health in advanced age. Older adults face higher risks of depression and anxiety due to health decline, poor living conditions, and limited support [38]. Furthermore, fear of tumor recurrence and treatment-related anxiety often increase with age, as autonomy decreases and social isolation rises [42]. Thus, both hypothalamic dysfunction and age-related psychosocial distress likely contribute to the greater impact of behavioral disorders on QoL in patients over 55.







### Nasal breathing disorders

The transsphenoidal approach for sellar and suprasellar lesions has been used in neurosurgery for over a century; however, the endonasal morbidity associated with this technique has only recently received scientific attention [26]. The nasal-sinus quality of life questionnaire, SNOT-22, was developed to assess symptoms in patients undergoing EEA [2].

In our questionnaire, patients reported symptoms such as nasal emptiness, nasal breathing difficulty, and taste or smell disturbances post-surgery, rating their impact on quality of life from 1 to 5. Our findings (Fig. 3E) align with a 2020 study by Shay et al., which showed that smokers undergoing EEA with nasoseptal flap reconstruction had worse total SNOT-22 scores compared to non-smokers [35]. Since all patients in our cohort had nasoseptal flap reconstruction, these results are consistent with existing literature. Notably, the study also found that smoking does not affect flap healing time [35].

ARTICLE IN PRESS



**A. Visual deficit****B. Obesity****C. Sleep disorders****D. Behavioral disorders****E. Nasal breathing disorders**

**Fig. 3** Statistical analysis of (A) visual deficit in relation to (a) postoperative worsening of visual function ( $p = 0.005$ ) and (b) sex ( $p = 0.012$ ); (B) obesity in relation to BMI ( $p = 0.039$ ); (C) sleep disorders in relation to histopathology ( $p = 0.026$ ). (D) behavioral disorders in relation to age ( $p = 0.010$ ); (E) nasal breathing disorders in relation to smoking ( $p = 0.023$ ). The circle indicates the mean, and the square indicates the median

### Pituitary stalk section role in patient quality of life

The management of craniopharyngiomas remains debated. Some advocate a conservative strategy of STR followed by radiotherapy to preserve pituitary function and minimize hypothalamic damage, especially in pediatric patients vulnerable to GH deficiency, obesity, and cognitive deficits[12]. This approach is based on the premise that STR combined with radiotherapy achieves tumor control rates comparable to GTR but with less morbidity. However, recurrence occurs in over one-third of cases with this strategy [40, 34]. Many studies comparing STR plus radiotherapy to GTR used craniotomy surgical approaches, which pose challenges in achieving GTR without significant comorbidities [34]. A 2021 national cohort study of 11,166 patients reported higher mortality and comorbidities after craniotomy GTR versus EEA [15].

With advances in endoscopic techniques, multiple studies have shown that GTR provides superior long-term tumor control, overall survival, and disease-free survival compared to STR with radiotherapy [28, 8, 3]. Preservation of the pituitary stalk, while reducing postoperative panhypopituitarism and diabetes insipidus, may increase recurrence risk due to microscopic residual tumor cells.

This highlights the critical role of EOR in craniopharyngioma management.



Nevertheless, pituitary stalk preservation is associated with lower rates of postoperative panhypopituitarism and diabetes insipidus [3] (Fig. 4A).

Our study specifically examined the impact of pituitary stalk section on long-term HRQoL in adults undergoing EEA. Given the balance between aggressive resection and preserving pituitary function, we assessed how stalk resection influences QoL. We grouped questionnaire items related to hormone replacement, weight, sexual function, sleep, and behavior into a “hypothalamic-pituitary functions” category. Analysis showed that stalk section worsens QoL, particularly through increased endocrinological therapy needs and hypothalamic disturbances. These dysfunctions had a greater negative effect in patients older than 55 years and those with stalk resection (Fig. 4B).

Therefore, in older patients, careful consideration is needed to balance resection extent with QoL implications. Preoperative counseling should involve patients in shared decision-making regarding the risks and benefits of stalk preservation versus resection to optimize surgical goals and postoperative QoL.

The retrospective design and the limited sample size represent the main limitations of this study. Moreover, both the patient-administered questionnaire and the assessment of QoL are inherently subjective, varying across individuals and therefore not consistently providing objective or unequivocal data.

Nevertheless, to our knowledge, this is the first attempt to investigate the correlation between long-term QoL and pituitary stalk section in adult patients with craniopharyngioma treated via EEA.

**A.****B. Hypothalamic-pituitary function**

**Fig. 4** (A) Association between pituitary stalk management and (a) EOR (univariate  $p = 0.014$ , multivariate  $p = 0.045$ ) and (b) postoperative worsening of endocrine function (univariate  $p = 0.011$ , multivariate  $p = 0.031$ ). (B) Association between hypothalamic–pituitary function and (a) age ( $p = 0.048$ ) and (b) pituitary stalk management ( $p = 0.034$ ). The circle indicates the mean, and the square indicates the median

## Conclusions

This study assessed long-HRQoL in adults undergoing EEA for craniopharyngioma, highlighting a significant correlation between QoL and pituitary stalk resection. While stalk section facilitates GTR, it substantially

worsens endocrine function, leading to impaired QoL, especially in patients older than 55 years. These findings emphasize the need to carefully balance the benefits and risks of pituitary stalk resection during surgery. Future multicenter, prospective studies are essential to provide further insights into this field and contribute to the development of management guidelines for the surgical treatment of these lesions.

### **Statements and Declarations**

**Funding:** No funding was received for conducting this study.

**Competing Interests:** The authors have no competing interests to declare that are relevant to the content of this article.

**Ethics approval:** All clinical and radiological data were collected and retrospectively analyzed. This study does not require any variations in patient's treatment and no formal ethics committee approval was required. All procedures performed for this study were in accordance with the ethical standard of author's Institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

ARTICLE IN PRESS

## References

1. Bellhouse J, Holland A, Pickard J. Psychiatric, cognitive and behavioural outcomes following craniopharyngioma and pituitary adenoma surgery. *Br J Neurosurg.* 2003;17(4). doi:10.1080/02688690310001601207
2. Bhenswala PN, Schlosser RJ, Nguyen SA, Munawar S, Rowan NR. Sinonasal quality-of-life outcomes after endoscopic endonasal skull base surgery. *Int Forum Allergy Rhinol.* 2019;9(10). doi:10.1002/alr.22398
3. Bobeff EJ, Mathios D, Mistry AA, et al. Predictors of extent of resection and recurrence following endoscopic endonasal resection of craniopharyngioma. *J Neurosurg.* 2023;139(5). doi:10.3171/2023.3.JNS222607
4. Bogusz A, Boekhoff S, Warmuth-Metz M, Calaminus G, Eveslage M, Müller HL. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. *Endocr Connect.* 2019;8(5). doi:10.1530/ec-19-0074
5. Bowers AR, Hughes L. Craniopharyngioma presenting with psychiatric symptoms: a case report. *Prog Neurol Psychiatry.* 2021;25(3). doi:10.1002/pnp.715
6. Calabrò RS, Cacciola A, Bruschetta D, et al. Neuroanatomy and function of human sexual behavior: A neglected or unknown issue? *Brain Behav.* 2019;9(12). doi:10.1002/brb3.1389
7. Castle-Kirsbaum M, Shi MDY, Goldschlager T. Quality of Life in Craniopharyngioma: A Systematic Review. *World Neurosurg.* 2022;164. doi:10.1016/j.wneu.2022.05.038
8. Cavallo LM, Frank G, Cappabianca P, et al. The endoscopic endonasal approach for the management of craniopharyngiomas: A series of 103 patients: Clinical article. *J Neurosurg.* 2014;121(1). doi:10.3171/2014.3.JNS131521
9. Daughters K, Manstead ASR, Rees DA. Hypopituitarism is associated with lower oxytocin concentrations and reduced empathic ability. *Endocrine.* 2017;57(1). doi:10.1007/s12020-017-1332-3
10. Daughters K, Unwin K, Rees DA. The psychological impact of adult-onset craniopharyngioma: A qualitative study of the experience of patients and clinicians. *European Journal of Oncology Nursing.* 2023;65. doi:10.1016/j.ejon.2023.102346
11. Dekkers OM, Biermasz NR, Smith JWA, et al. Quality of life in treated adult craniopharyngioma patients. *Eur J Endocrinol.* 2006;154(3). doi:10.1530/eje.1.02114
12. Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: Hypothalamus-sparing surgery decreases the risk of obesity. *Journal of Clinical Endocrinology and Metabolism.* 2013;98(6). doi:10.1210/jc.2012-3928
13. Fick DM, Semla TP, Steinman M, et al. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc.* 2019;67(4). doi:10.1111/jgs.15767

14. Garrahy A, Moran C, Thompson CJ. Diagnosis and management of central diabetes insipidus in adults. *Clin Endocrinol (Oxf)*. 2019;90(1). doi:10.1111/cen.13866
15. Govindarajan V, Luther EM, Morell AA, et al. Perioperative Complications in Endoscopic Endonasal versus Transcranial Resections of Adult Craniopharyngiomas. *World Neurosurg*. 2021;152. doi:10.1016/j.wneu.2021.06.066
16. Kawamata T, Amano K, Aihara Y, Kubo O, Hori T. Optimal treatment strategy for craniopharyngiomas based on long-term functional outcomes of recent and past treatment modalities. *Neurosurg Rev*. 2010;33(1). doi:10.1007/s10143-009-0220-6
17. Lania A, Spada A, Lasio G. Diagnosis and Management of Craniopharyngiomas.; 2016. doi:10.1007/978-3-319-22297-4
18. Lin B, Xiang S, Chen J, et al. Assessment of quality of life in patients with craniopharyngioma and identification of risk factors for compromised overall wellness. *Arch Endocrinol Metab*. 2024;68. doi:10.20945/2359-4292-2023-0001
19. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. *Neuro Oncol*. 2021;23(8). doi:10.1093/neuonc/noab106
20. Lucia K, Vajkoczy P, Kaul D, Strasburger CJ, Onken J. Health-Related Quality of Life in Adult Patients with Craniopharyngioma. *World Neurosurg*. 2021;154. doi:10.1016/j.wneu.2021.06.119
21. Massimi L, Palombi D, Musarra A, et al. Adamantinomatous craniopharyngioma: evolution in the management. *Child's Nervous System*. 2023;39(10). doi:10.1007/s00381-023-06143-4
22. Monzani ML, Pederzoli S, Volpi L, Magnani E, Diazi C, Rochira V. Sexual Dysfunction: A Neglected and Overlooked Issue in Adult GH Deficiency: The Management of AGHD Study. *J Endocr Soc*. 2021;5(3). doi:10.1210/jeendo/bvab002
23. Müller HL, Bruhnken G, Emser A, et al. Longitudinal study on quality of life in 102 survivors of childhood craniopharyngioma. *Child's Nervous System*. 2005;21(11). doi:10.1007/s00381-004-1124-y
24. Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. *Nat Rev Dis Primers*. 2019;5(1). doi:10.1038/s41572-019-0125-9
25. Müller HL. Craniopharyngioma and hypothalamic injury: Latest insights into consequent eating disorders and obesity. *Curr Opin Endocrinol Diabetes Obes*. 2016;23(1). doi:10.1097/MED.0000000000000214
26. Novák V, Hrabálek L, Hoza J, C.Hučko, Pohlodek D, Macura J. Sinonasal quality of life in patients after an endoscopic endonasal surgery of a sellar tumour. *Sci Rep*. 2021;11(1). doi:10.1038/s41598-021-02747-5
27. Nozaki A, Ando T, Akazawa S, et al. Quality of life in the patients with central diabetes insipidus assessed by Nagasaki Diabetes Insipidus Questionnaire. *Endocrine*. 2016;51(1). doi:10.1007/s12020-015-0637-3
28. Ordóñez-Rubiano EG, Forbes JA, Morgenstern PF, et al. Preserve or sacrifice the stalk? Endocrinological outcomes, extent of resection, and

- recurrence rates following endoscopic endonasal resection of craniopharyngiomas. *J Neurosurg.* 2019;131(4). doi:10.3171/2018.6.JNS18901
29. Pascual JM, Prieto R, Rosdolsky M. Craniopharyngiomas primarily affecting the hypothalamus. In: *Handbook of Clinical Neurology.* Vol 181. 2021. doi:10.1016/B978-0-12-820683-6.00007-5
  30. Patel KS, Raza SM, McCoul ED, et al. Long-term quality of life after endonasal endoscopic resection of adult craniopharyngiomas. *J Neurosurg.* 2015;123(3). doi:10.3171/2014.12.JNS141591
  31. Qi Songtao, Pan Jun, Lu Yuntao. *Frontiers in Neurosurgery.* Volume 4, Craniopharyngiomas -- Classification and Surgical Treatment. Bentham Science Publishers; 2017.
  32. Romigi A, Feola T, Cappellano S, et al. Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update. *Front Neurol.* 2022;12. doi:10.3389/fneur.2021.817257
  33. Salvio G, Martino M, Giancola G, Arnaldi G, Balercia G. Hypothalamic–pituitary diseases and erectile dysfunction. *J Clin Med.* 2021;10(12). doi:10.3390/jcm10122551
  34. Schoenfeld A, Pekmezci M, Barnes MJ, et al. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. *J Neurooncol.* 2012;108(1). doi:10.1007/s11060-012-0806-7
  35. Shay A, Sturgis M, Ritz EM, et al. Prior smoking and nasoseptal flap usage adversely impact quality of life and healing after endoscopic pituitary surgery. *Neurosurg Focus.* 2020;48(6). doi:10.3171/2020.3.FOCUS2050
  36. Sinai J, Wong AHC. Craniopharyngeoma presenting as psychosis, disinhibition and personality change without neurological signs. *Acta Neuropsychiatr.* 2003;15(2). doi:10.1034/j.1601-5215.2003.00013.x
  37. Wolf A, Coros A, Bierer J, et al. Quantitative evaluation of vision-related and health-related quality of life after endoscopic transsphenoidal surgery for pituitary adenoma. *J Neurosurg.* 2017;127(2). doi:10.3171/2016.7.JNS16200
  38. World Health Organization. Mental health of older adults.
  39. Xiao G, Yuan X, Yuan J, et al. Pituitary stalk management during the microsurgery of craniopharyngiomas. *Exp Ther Med.* 2014;7(5). doi:10.3892/etm.2014.1561
  40. Yang I, Sughrue ME, Rutkowski MJ, et al. Craniopharyngioma: A comparison of tumor control with various treatment strategies. *Neurosurg Focus.* 2010;28(4). doi:10.3171/2010.1.FOCUS09307
  41. Yang L, Xie SH, Tang B, et al. Hypothalamic injury patterns after resection of craniopharyngiomas and correlation to tumor origin: A study based on endoscopic observation. *Cancer Med.* 2020;9(23). doi:10.1002/cam4.3589
  42. Zada G, Kintz N, Pulido M, Amezcua L. Prevalence of neurobehavioral, social, and emotional dysfunction in patients treated for childhood craniopharyngioma: A systematic literature review. *PLoS One.* 2013;8(11). doi:10.1371/journal.pone.0076562
  43. Zhou Z, Zhang S, Hu F. Endocrine Disorder in Patients With Craniopharyngioma. *Front Neurol.* 2021;12. doi:10.3389/fneur.2021.737743

44. Myneni S, Bhandarkar S, Akbari H, et al. The Craniopharyngioma Quality of Life (C-QOL) Index: a preliminary disease-specific, patient-centered tool for assessing patient reported outcomes in adult craniopharyngioma patients. *J Neurooncol*. 2025 Oct 27;176(1):45. doi: 10.1007/s11060-025-05284-7. PMID: 41143938.

ARTICLE IN PRESS